Since drugs improving neural GCase activity might also reduce α-synuclein levels and thereby improve PD prognosis, studies are underway to develop therapies that can overcome the blood-brain barrier and rescue neuronal pathology [17]. This evidence concerns the gene SNCA and Parkinson disease.